Birdwatch Archive - Rating Details

Birdwatch Note Rating

2023-07-09 17:17:34 UTC - SOMEWHAT_HELPFUL

Rated by Participant: 8DA04521E5F779D5C71BA693DB20C3DC536D4C5D0B93050A0BF360BC82E4CFDF
Participant Details

Original Note:

The Phase 3 LUCIDITY trial for hydromethylthionine mesylate (HMTM) failed to meet its endpoint as reported on Medscape. Additional trials are underway. The LUCIDITY trial did have encouraging results that TauRx Pharmaceuticals are promoting through PR releases. https://www.prnewswire.com/in/news-releases/lucidity-phase-3-topline-data-presented-at-ctad-for-hmtm--the-only-oral-anti-tau-therapy-in-late-stage-development-301690475.html https://www.medscape.com/viewarticle/984863 https://archive.is/awWDp

All Note Details

Original Tweet

All Information

noteId - 1677803233077522432
participantId -
raterParticipantId - 8DA04521E5F779D5C71BA693DB20C3DC536D4C5D0B93050A0BF360BC82E4CFDF
createdAtMillis - 1688923054345
version - 2
agree - 0
disagree - 0
helpful - 0
notHelpful - 0
helpfulnessLevel - SOMEWHAT_HELPFUL
helpfulOther - 0
helpfulInformative - 0
helpfulClear - 0
helpfulEmpathetic - 0
helpfulGoodSources - 0
helpfulUniqueContext - 0
helpfulAddressesClaim - 1
helpfulImportantContext - 0
helpfulUnbiasedLanguage - 0
notHelpfulOther - 0
notHelpfulIncorrect - 0
notHelpfulSourcesMissingOrUnreliable - 0
notHelpfulOpinionSpeculationOrBias - 0
notHelpfulMissingKeyPoints - 0
notHelpfulOutdated - 0
notHelpfulHardToUnderstand - 1
notHelpfulArgumentativeOrBiased - 0
notHelpfulOffTopic - 0
notHelpfulSpamHarassmentOrAbuse - 0
notHelpfulIrrelevantSources - 0
notHelpfulOpinionSpeculation - 0
notHelpfulNoteNotNeeded - 0
ratingsId - 16778032330775224328DA04521E5F779D5C71BA693DB20C3DC536D4C5D0B93050A0BF360BC82E4CFDF